A5086382821- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Economic and Financial Impacts of Cancer
- Retinoids in leukemia and cellular processes
- Hepatocellular Carcinoma Treatment and Prognosis
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Treatment and Research
- Gastric Cancer Management and Outcomes
- Multiple and Secondary Primary Cancers
- Neutropenia and Cancer Infections
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- Bacterial Identification and Susceptibility Testing
- Head and Neck Cancer Studies
- Blood disorders and treatments
- Management of metastatic bone disease
- PARP inhibition in cancer therapy
- Multiple Myeloma Research and Treatments
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2023
BeiGene (China)
2021-2023
Sanofi (United States)
2017-2018
Fédération française de cardiologie
2018
InGen (France)
2018
Teva Pharmaceuticals (United States)
2014-2015
Teva Pharmaceuticals (Hungary)
2014
Health Economics and Outcomes Research (United Kingdom)
2014
Addenbrooke's Hospital
2005
RATIONALE 302 (NCT03430843) an open-label, phase III study of second-line treatment advanced/metastatic esophageal squamous cell carcinoma (ESCC), reported that tislelizumab, relative to investigator-chosen chemotherapy (ICC), was associated with improvements in overall survival and a favorable safety profile. This assessed the health-related quality life (HRQoL) ESCC-related symptoms patients 302.Adults ESCC whose disease progressed following prior systemic therapy were randomized 1 :...
366 Background: While improved survival has been previously demonstrated, the impact of immunotherapy on HRQoL in ESCC not well examined. Traditional PRO-based analyses oncology trials, such as time to deterioration (TTD) and mixed models for repeated measures (MMRMs), are limited by discounting recurrent PRO events. Thus, we applied a 3-component joint model (JM) framework define more clinically interpretable associations between patient-reported symptoms, treatment effects, OS among...
365 Background: The relationship between patient-reported outcome (PRO)-based symptom scores, recurrent PRO-based symptomatic deterioration events (RDEs), and terminal such as progression-free survival (PFS) are rarely examined in the oncology therapeutic domain. Thus, we applied a 3-component joint model (JM) framework aiming to illuminate more clinically interpretable associations treatment effects, RDEs, PFS among subgroups of patients with programmed death-ligand 1 (PD-L1) expression...
290 Background: RATIONALE-305 (NCT03777657), demonstrated statistically significant and clinically meaningful improvements in overall survival (OS) with TIS + chemo (n=501) over PBO (n=496) as 1L treatment patients (pts) advanced G/GEJC. This analysis examined HRQoL outcomes of the study at final analysis. Methods: Adults previously untreated, unresectable, or metastatic GC/GEJC, were randomized (1:1) to 200 mg IV once every 3 weeks plus investigator-choice chemo. was assessed using EORTC...
The purpose of this analysis was to assess health-related quality life (HRQoL) in patients treated with zanubrutinib and ibrutinib the ALPINE trial (NCT03734016).
To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration-resistant prostate cancer (mCRPC) and to describe physician-assessed effectiveness, health-related quality of life (HRQoL) safety.CAPRISTANA was an international, observational cohort study examining use the treatment mCRPC. Effectiveness assessed by overall survival (OS), progression-free (PFS), time failure (TTF) disease control rate. HRQoL using Functional Assessment Cancer...
•2L tislelizumab for advanced/metastatic ESCC prolonged OS versus chemotherapy in a Europe/North America subgroup.•Tislelizumab had more favorable safety profile the patient subgroup.•Tislelizumab's efficacy and subgroup were consistent with overall trial population.•Results support potential to become 2L option advanced Western countries. BackgroundThe phase III RATIONALE-302 study evaluated tislelizumab, an anti-programmed cell death protein 1 antibody, as second-line (2L) treatment...
This study assessed the effects of adding tislelizumab to first-line standard-of- care chemotherapy on health-related quality life (HRQoL) patients with advanced squamous non-small cell lung cancer (sq-NSCLC).Patients in this open-label, multicenter, phase 3 RATIONALE 307 trial were randomized one three arms: plus carboplatin and paclitaxel (Arm A), nab-paclitaxel B), or C). HRQoL was measured using European Organization for Research Treatment Cancer (EORTC) Quality Life Questionnaire Core...
Abstract Background This study evaluated health‐related quality of life (HRQoL) in the RATIONALE‐309 (NCT03924986) intent‐to‐treat (ITT) population and a subgroup patients with liver metastases. Methods Patients were randomized 1:1 to tislelizumab + chemotherapy or placebo chemotherapy. As secondary endpoint, HRQoL was using seven selected scores from EORTC QLQ‐C30 QLQ Head Neck Cancer module (QLQ‐H&N35). Results Of 263 ITT (tislelizumab n = 131, 132), 43% had metastases 56; 57). No...
Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 EQ-5D-5L VAS scores. Results: Overall, 201 (102 zanubrutinib; 99 ibrutinib) enrolled. Clinically meaningful differences observed diarrhea nausea/vomiting both intent-to-treat population attaining very good partial response (VGPR) earlier...
Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety zanubrutinib ibrutinib in patients WM. This ad hoc analysis examined treatment outcomes or on PN symptoms WM enrolled ASPEN. Logistic regression was performed between symptom resolution several predictors. Health-related quality life (HRQOL) assessed using validated European Organization for Research Treatment Cancer...
Purpose This study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus alone as first-line treatment on health-related quality life (HRQoL) patients advanced nonsquamous non–small lung cancer (nSQ-NSCLC). Methods Patients this randomized, open-label, multicenter phase III RATIONALE 304 (NCT03663205) histologically confirmed stage IIIB/IV nSQ-NSCLC were randomized 2:1 to tislelizumab plus platinum-pemetrexed (arm T + PP)...
The objective of this study was to estimate the net cost arsenic trioxide (ATO) added all-trans retinoic acid (ATRA) compared ATRA plus chemotherapy when used in first-line acute promyelocytic leukemia (APL) treatment for low intermediate risk patients from perspective overall Italian healthcare systemA Markov model developed with 3 health states: stable disease, disease event and death. Each month, could move or die either state. After a event, discontinued initial switched other regimen as...
Introduction Esophageal cancer (EC) makes up 3.2% of all cancers but ranks sixth among cancer-related deaths worldwide. This real-world analysis determined the use PD-1/PD-L1 (PD[L]1) inhibitors in EC patients after receiving first-line therapy.Methods Newly diagnosed initiating treatment were identified IBM MarketScan administrative claims databases during study period (1 May 2015 to 31 October 2020) using ICD-9/ICD-10 codes. Patients assigned either chemotherapy only, radiation plus...
This study examined the health-related quality of life (HRQoL) patients with advanced non-small cell lung cancer (NSCLC) receiving tislelizumab versus docetaxel in open-label, multicenter, Phase 3 trial called RATIONALE-303 (NCT03358875). HRQoL was assessed EORTC QLQ-C30, QLQ-LC13, and EQ-5D-5L instruments. A longitudinal analysis covariance change from baseline to Week 12 18. time deterioration also performed using Kaplan-Meier method. Eight hundred five were randomized either (n = 535) or...
Zanubrutinib is a highly selective, next-generation Bruton's tyrosine kinase inhibitor. In the phase 3 SEQUOIA trial (NCT03336333), treatment with zanubrutinib resulted in significantly improved progression-free survival compared to bendamustine plus rituximab (BR) adult patients treatment-naïve chronic lymphocytic leukemia (CLL) and small lymphoma (SLL) without del(17p). The current analysis effects of versus BR on patients' health-related quality-of-life (HRQoL).
Post-hoc analysis examined health-related quality of life and esophageal squamous cell carcinoma (ESCC) symptoms in the Asian subgroup patients RATIONALE-302 (NCT03430843).
Differences in healthcare utilization and costs were examined chronic myeloid leukemia (CML) patients experiencing first-, second- third-line tyrosine kinase inhibitor (TKI) therapy. Three CML cohorts identified from the Truven Health MarketScan® database: No-Switch Cohort (NSc) = did not switch first-line; One-Switch (OSc) switched first- to second-line only; Two-Switch (TSc) then third-line. A total of 3510 (mean 54%; age 55.8 years). NSc comprised 81% sample, OSc 15% 4% TSc. First-line...